Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
1991-3-8
pubmed:abstractText
Diabetes mellitus was assessed by investigating 8 type I diabetic patients, in good metabolic control and with congestive heart failure, who were studied after 3 weeks of placebo and ibopamine (100 mg t.i.d.) treatment. Metabolic control and daily insulin dose did not change in any patient during the study. The insulin-mediated glucose uptake during the clamp studies showed no variation after placebo or ibopamine therapy. Total cholesterol, HDL-cholesterol and triglycerides concentrations remained unchanged. This study clearly suggests that ibopamine administered at a daily dose of 300 mg for 3 weeks presents a metabolic safety in type I diabetic patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0008-6312
pubmed:author
pubmed:issnType
Print
pubmed:volume
77 Suppl 5
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
63-6
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:year
1990
pubmed:articleTitle
Ibopamine does not affect insulin resistance in patients with type I diabetes.
pubmed:affiliation
Chair of Metabolic Disease, University of Pisa, Italy.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial